Paratek Pharmaceuticals’ Post

Genemarkers is excited to be recognized as one of the Top Pharmacogenomic (PGx) Service Providers of 2023 by Pharma Tech Outlook. We are proud to be at the forefront of the clinical implementation of PGx testing. Learn more: https://lnkd.in/e9DGib-q #PharmacogenomicTesting #PGxTesting #Pharmacogenomics #GeneExpression #DiagnosticTesting #PrecisionMedicine #PersonalizedMedicine #DNA #GeneticTesting

Today, at USBio'24 in San Diego, 🇺🇸? If so, join the #orphan and #rare disease presentations track (Theater 4) and watch live Avanzanite Bioscience corporate presentation. Eva Cruz de Castro will emphasise what is the role of #orphan specialty pharmaceutical company and our strong beliefs to ensure that NO ONE IS LEFT BEHIND when facing monstrous #rare diseases. She will also share our view on the evolving #orphandrug market with anticipated 800+ R&D programs in the global biotechs. And options available for partners how to make their innovations available in Europe and globally. You should particularly watch Eva Cruz de Castro if you face challenges in Europe 🇪🇺 and beyond. Perhaps, there are very few patients that could use your medicine. Or the market access issues are overwhelming. Or simply, you only have a bandwith to go to to 2–3 countries at launch. At Avanzanite Bioscience, whatever is the trouble, we love challenges.

This week's @Pearce IP #BioBlast features the following (and more!):   - #semaglutide: Novo Nordisk #Ozempic® semaglutide 1.0 study demonstrates reduction in kidney disease events  - #adalimumab #ustekinumab: Samsung Bioepis presents interchangeability updates for its adalimumab and ustekinumab biosimilars at AAD  - #aflibercept: Biocon Settles aflibercept dispute with Regeneron & Bayer; announces Canadian launch date  - #ustekinumab: Amgen launches second #Stelara® (ustekinumab) biosimilar in Canada  - #tocilizumab: Fresenius Kabi announces first subcutaneous tocilizumab biosimilar approved in the US   - #denosumab: Sandoz announces first US denosumab biosimilars approved with interchangeability  - #ranibizumab: Sandoz completes acquisition of Coherus’s #CIMERLI® (ranibizumab biosimilar)         Read more: https://lnkd.in/gkWBzdhU    #bioblast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma #lifesciences #femalefounder  

Could this be the biggest week ever for the Pearce IP #BioBlast? We have reported global biosimilars developments weekly since 2015, but I do not recall a week this active! - Novo Nordisk's #Ozempic® - Samsung Bioepis's #adalimumab #ustekinumab interchangeability biosimilars; - Biocon's #aflibercept - Amgen's #Stelara® (#ustekinumab) - Sandoz's interchangeable #denosumab - Sandoz/Coherus BioSciences’ #CIMERLI® (#ranibizumab)     - Fresenius Kabi's #tocilizumab  Read more below   #bioblast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #patents #biopharma #lifesciences #femalefounder 

If you missed this webinar you can listen to the recording

🔎 🍒 Discover CubiX - A Complex Representation of Human's Biology  The CubiX platform was designed with the unique needs of pharmaceutical companies, laboratories, and research hospitals in mind - it allows scientists to validate at an early stage (before clinical trials) the safety and efficacy of the drug under development 🔬. What more? CubiX offers an ultimate alternative to the animal testing model that is fully-aligned with the FDA Modernization Act 2.0. We are proud to be able to offer this sustainable innovative solution to the industry 🐇. 🌟 CubiX at a glance: ✔️ Hypoxia and/or normoxia ✔️ Long term cell culture (>15 days) ✔️ Compatible with primary cells ✔️ Real-time monitoring (pH, lactose, glucose, O2) Check out CubiX platform and see how it could be a good fit for your research: https://lnkd.in/ekNxXfkg #3dcellculture #alternativestoanimaltesting #organoids #immunocompetent #vascularized 

LBA member and Genflow Biosciences CEO Dr. Eric Leire shared updates on their progress and future plans. Key points include: -Secured funding to advance programs, particularly lead candidate GF-1002, with guidance from the FDA and European Agency. -Focus on global reach, aligning efforts in Europe and the US. -Promising results in clinical trials for dogs with sirtuin 6 (SIRT6) variants, which could expedite human trials. -Collaboration with Exothera S.A. for cost-effective large-scale production of SIRT6 variants. -Upcoming focus on clinical trials for MASH and advancing the dog study, with potential veterinary pharmaceutical collaborations.

-Biogen and Ionis announce the discontinuation of BIIB105, an investigational drug for ALS. -Despite successfully lowering ATXN2 protein, BIIB105 did not demonstrate effectiveness in slowing the disease process, prompting the decision to terminate its development. -Both companies express gratitude to study participants and investigators while affirming continued commitment to developing treatments for ALS. To know more, read the full article on #theenterprise #Biogen #IonisPharmaceuticals #ALSResearch #BIIB105 #ClinicalTrials#globalbusiness #theenterprisenews #followformore #global #finance

Join Novotech for an informative webinar on May 8, 2024, at 3-4 pm CST, where we will explore the Bioassay Platform for Small Nucleic Acid Drug Analysis: PK, PD, and Immunogenicity. Our experts, Ian Yeh (葉斯寧) and Thomas Tang (湯偉辰), will do a deep dive into the importance of bioassays in advancing clinical drug development and meeting the demands of monitoring therapeutic drugs. Register now and gain the insights needed into one of the most dynamic areas in drug development. #Bioassay #ClinicalTrials #Novotech

Clinical stage #biotech company Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has released a new investor presentation as the company presents at the Ord Minnett #Healthcare Forum.  Recce is at the forefront of developing a new class of synthetic #antiinfectives to combat antibiotic-resistant #superbugs and emerging viral pathogens. The company's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327, RECCE® 435, and RECCE® 529. These innovative therapies have the potential to overcome the challenges posed by bacterial and viral mutations that have rendered traditional #antibiotics less effective. More at http://ow.ly/qq5X104ZEAJ #ASX #OTC #RCE #RECEF #Reece #Proactive #ProactiveInvestors